Pre-Announcement: CIHR-JDRF Team Grants: Precision Medicine in Type 1 Diabetes (Anticipatory)

CIHR and JDRF Canada are pleased to provide information about a potential funding opportunity we anticipate launching in the near future. It stems from the 2021 Federal Budget announcement on strategic investments in diabetes research.

While this funding opportunity has yet to be finalized, CIHR and JDRF Canada are providing preliminary information at this time to allow the community to prepare and respond to what will be an expedited process.

Overview

Precision medicine is an important “approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle^{Footnote 1}. Often described as the provision of the right treatment for the right patient at the right time, precision medicine focuses on integrating multidimensional data about genetic, molecular, and environmental factors to improve disease diagnosis, care, treatment or prevention. A greater understanding of how individual characteristics ‒ including in genetic profiles, biomarkers and immune and beta cell dysfunction ‒ contribute to type 1 diabetes (T1D) risk and progression, may lead to identification of more precise therapeutic targets, better characterization of disease risk, initiation and progression, improved opportunities for safe and effective intervention and, ultimately, prevention of T1D.

Building on the expertise developed through CIHR’s Personalized Health Initiative and complementing previous CIHR and JDRF investments in new research as part of 100 Years of Insulin: Accelerating Canadian Discoveries to Defeat Diabetes, the CIHR-JDRF Team Grants: Precision Medicine in Type 1 Diabetes will support multi-disciplinary research to characterize disease heterogeneity and accelerate precision medicine approaches for prediction, prevention and treatment of T1D.

Objectives

The objectives of this funding opportunity are:

• To generate knowledge regarding the heterogeneity of T1D that will enable and inform new precision medicine approaches for the prediction, prevention, care or treatment of T1D
• To advance curative and disease-modifying therapies for T1D using precision medicine approaches.

Funds available

The anticipated total amount available for this funding opportunity is $14,000,000, enough to fund approximately 4 grants. The maximum amount per grant is $875,000 per year for up to 4 years, for a total of $3,500,000 per grant.

Anticipated timeline

These dates are estimates and subject to change.

• Program Launch: May 2022
• Registration:  June 2022
• Application Deadline: August 2022
• Notice of Decision: January 2023

Date modified:

2022-06-21